Quick summary
SYN-AKE is a patented synthetic tripeptide mimicking Temple Pit Viper venom (Waglerin-1) that relaxes facial muscles by competitively antagonizing the nicotinic acetylcholine receptor. In vitro studies showed up to 80% reduction in muscle contraction signaling.
Overview
SYN-AKE is a patented synthetic tripeptide that mimics the paralytic action of Waglerin-1, a peptide component of the venom of the Temple Pit Viper (Tropidolaemus wagleri). Developed by DSM (formerly Pentapharm), it works by transiently relaxing facial muscles responsible for expression wrinkles. Unlike Argireline-class peptides that target the SNARE complex, SYN-AKE acts directly at the nicotinic acetylcholine receptor.
Mechanism of action
SYN-AKE acts as a competitive antagonist at the muscular nicotinic acetylcholine receptor (mnAChR). In normal neuromuscular transmission, acetylcholine binds mnAChR to trigger muscle fiber contraction. SYN-AKE competes for this receptor binding site, reducing the efficiency of signal transduction without blocking it completely. This partial inhibition attenuates facial muscle contractility in a reversible and dose-dependent manner, reducing the mechanical stress that deepens expression lines. In vitro studies showed up to 80% reduction in muscle contraction signaling at effective concentrations.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| expression wrinkle reduction | topical | 4–4 % | twice daily | Typical use concentration is 4% in finished serum. Apply to forehead, crow's feet, and perioral area. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
In vitro receptor-binding studies show up to 80% attenuation of mnAChR-driven muscle contraction. A 28-day clinical trial reported significant reduction in wrinkle depth and skin smoothness improvements observable by digital imaging. Effect is fully reversible and non-paralytic. All published evidence is from the manufacturer or cosmetic ingredient suppliers; no independent RCTs as of 2026.[1][2][3]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with SYN-AKE for synergistic effects.
Legal status
OTC cosmetic ingredient. Approved for use in skincare formulations in EU, US, and major markets. The 'snake venom' branding is marketing — the active is a synthetic analog with no actual venom.
Sourcing & access
Research compound
SYN-AKE is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
SYN-AKE is a patented synthetic tripeptide developed by DSM that mimics the active component of Waglerin-1, a toxin from the Temple Pit Viper (Tropidolaemus wagleri). It is entirely synthetic — no actual venom is used. It is marketed as a cosmetic peptide for reducing expression lines and is included in premium anti-aging formulations as a topical venom mimic.
SYN-AKE acts as a competitive antagonist at the muscular nicotinic acetylcholine receptor (mnAChR) at the neuromuscular junction of facial muscles. By reducing acetylcholine receptor activation, it decreases muscle contraction efficiency at treated sites. The effect is reversible and non-paralytic, unlike botulinum toxin, with normal muscle function maintained but contraction intensity reduced during topical application.
SYN-AKE is an approved OTC cosmetic ingredient in the EU, United States, and most major global markets. It has undergone the standard cosmetic ingredient safety review process. Reported side effects are mild and include a transient tingling or warm sensation at application, which some users notice during the first applications, and rare mild redness. All effects are fully reversible and non-paralytic.
In vitro studies report up to 80 percent attenuation of mnAChR-driven muscle contraction at effective concentrations. A 28-day clinical trial showed statistically significant wrinkle depth reduction compared to baseline. However, all published efficacy evidence is manufacturer-sourced (DSM), and no independent peer-reviewed clinical trials have replicated these results. This limits the strength of efficacy conclusions.